Please assess the completion status of the following clinical trial:

Trial Title: Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years, inclusive~* current Diagnostic \& Statistical Manual of Mental Disorders 4th ed (DSM-IV) alcohol dependence (within the past month)~* have 2 heavy drinking days per week during the period between screening and baseline (defined as \>4 standard drinks per day for males, and \>3 standard drinks per day for females)~* able to read at the eighth grade or higher level and show no evidence of significant cognitive impairment~* if a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or who is less than two years postmenopausal), must be non-lactating, practicing a reliable method of birth control including barrier method; and have a negative serum pregnancy test prior to initiation of treatment~* be willing to provide signed, informed consent to participate in the study~Exclusion Criteria:~* have a current, clinically significant physical disease or abnormality (i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities such as hepatic aminotransferase levels greater than 300% of the uper limit of normal or direct bilirubin levels 150% of the upper limit of normal) on the basis of medical history, physician examination, or routine laboratory evaluation. Serum creatinine level of \> 1.2 mg/dl will also be exclusionary. Other specific exclusionary disorders include:~  * patients with a history of renal calculi~ * patients with a history of hypersensitivity to zonisamide or any sulfonamide, Stevens-Johnson Syndrome, penicillin allergy, or history of any severe drug allergic reaction~ * patients with a significant history of systemic autoimmune disease such as lupus erythematosis, fibromyalgia, or rheumatoid arthritis~ * patients with a current blood dyscrasia or a history of such, with the exception of a remote history of iron deficient anemia~* have a serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, panic disorder, or substantial suicide or violence risk) on the basis of history or psychiatric examination~* current dependence on opioids or benzodiazepines or other sedatives will also be exclusionary~* are considered by investigators to be clinically inappropriate for study participation~* because individuals with a history of seizure disorder could potentially be at increased risk of experiencing a seizure due to their drinking, such individuals will also be excluded~* have participated in another pharmacotherapy study in the past thirty days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Zonisamide
- B (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).